CPT code 86689 represents a laboratory confirmatory antibody test, commonly a Western blot, used to verify reactive screening results for HTLV or HIV. This confirmatory assay is clinically important because it establishes or rules out infection after initial serologic or screening tests, guiding patient management, public health reporting, and infection control measures. Nationally, confirmatory testing remains a critical component of diagnostic pathways for retroviral infections and influences laboratory workflows and payer coverage policies.

Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find benchmarks for utilization and billing practices, a clinical context explaining when 86689 is used in diagnostic algorithms, and summaries of common billing considerations relevant to payers. The content outlines typical sites of service and the nature of the procedure without offering clinical recommendations.

This publication is intended to help billing managers, laboratory directors, and health policy stakeholders understand the role of CPT code 86689, how it fits into confirmatory testing workflows, and what payer coverage patterns and policy implications are commonly associated with confirmatory antibody testing for HTLV and HIV.